A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

Prior treatment

• Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin;
• Use of NSAIDs within 1 week before first dose of investigational product
• Known or suspected allergies to the investigational product or any of its components;
• Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment;

Other illness

• Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years);

• Age ≥18 years old and \<75 years old at the time of signing the informed consent form, regardless of gender;
• Active rheumatoid arthritis, ESR or C-reactive protein\> upper limit of normal
• Meets the 2010 American College of Rheumatology ACR/EULAR RA classification standards
• Participants have recovered from adverse reactions to previous antirheumatic treatment.